All In Biotech

Drug Trial Radar · NCT01235741

A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects

A Randomized, Double-Blind, Placebo-Controled, Multicenter Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects Following A Low-Calorie Diet Lead-In

Last checked: Nov 20, 2026Latest source record: Apr 15, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 213 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

213

Actual

Start

Jan 2011

Primary completion

Sep 2011

Study completion Sep 2011

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Takeda Pharmaceuticals North America, Inc.
First posted
Nov 8, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Following screening, eligible subjects will be enrolled into a 6-week Low Calorie Diet (LCD) lead-in period. Subjects who lose at least 2% of their body weight at the end of the 6-week LCD lead-in period will be randomized to 1 of 2 treatment arms (pramlintide+metreleptin or placebo) to begin a 16-week treatment period during which the effect on body weight of treatment with pramlintide+metreleptin will be compared to placebo. Following the 16 week blinded core treatment period, subjects will discontinue study medication for a period of 12 weeks. Following the 12 week off-drug follow-up period, subjects in both groups will initiate a 12 week open-label treatment period with Pramlintide+Metreleptin. During the 12 week off-drug and 12 week open label treatment periods, subjects will continue to participate in a Lifestyle Intervention (LSI) program.

Conditions

  • Obesity

Interventions

  • Pramlintide+MetreleptinDrug

    Group A: Subcutaneous Injection once a day (QD): Pramlintide 360 mcg+Metreleptin 5.0 mg for 1 week followed by Pramlintide 360 mcg+Metreleptin 5.0 mg twice a day (BID) for 15 weeks.

  • PlaceboDrug

    Group B: Subcutaneous Injection-twice a day (BID): Placebo equivalent volumes to active doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events and Number With Post Treatment Adverse Events - Intent to Treat PopulationTime frame: Day 1 up to Month 6 Follow-Up
  2. Change From Baseline to Week 2, and to Follow up Months 2, 4, 6 in Fasting Leptin Concentration - Intent to Treat PopulationTime frame: Baseline to Month 6 Follow Up
  3. Number of Participants With Anti-leptin Antibodies Who Received Metreleptin - Intent to Treat PopulationTime frame: Week 1 to Month 6 Follow-Up
  4. Number of Participants With Neutralizing Activity to Metreleptin at Early Termination or During Post Treatment Follow-Up - Intent to Treat Population Who Received MetreleptinTime frame: Baseline to Month 6 Follow-Up
  5. Number of Participants With Hematology and Urinalysis Laboratory Values of Potential Clinical Importance - Intent to Treat PopulationTime frame: Screening to 6 Month Follow-Up
  6. Number of Participants With Chemistry Laboratory Value of Potential Clinical Importance - Intent to Treat PopulationTime frame: Screening to Month 6 Follow-Up
  7. Mean Change From Baseline to Month 6 Follow-Up in Blood Pressure - Intent to Treat PopulationTime frame: Baseline to Month 6 Follow-Up
  8. Mean Change From Baseline to Month 6 Follow-Up in Heart Rate - Intent to Treat PopulationTime frame: Baseline up to Month 6 Follow-Up
  9. Mean Change From Baseline to 6 Month Follow-Up in Fasting Plasma Glucose - Intent to Treat PopulationTime frame: Baseline to 6 Month Follow-Up
  10. Mean Change From Baseline to Month 6 Follow-Up in Insulin - Intent to Treat PopulationTime frame: Baseline up to Month 6 Follow-Up
  11. Mean Change From Baseline to Month 6 Follow-Up in Lipids - Intent to Treat PopulationTime frame: Baseline up to Month 6 Follow-Up

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Greenbrae, California

  • Research Site

    La Jolla, California

  • Research Site

    Denver, Colorado

  • Research Site

    Winter Park, Florida

  • Research Site

    Chicago, Illinois

  • Research Site

    Baton Rouge, Louisiana

  • Research Site

    Hyattsville, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    St Louis, Missouri

  • Research Site

    Butte, Montana

  • Research Site

    New York, New York

  • Research Site

    Tulsa, Oklahoma

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Austin, Texas

  • Research Site

    Salt Lake City, Utah

  • Research Site

    Arlington, Virginia

  • Research Site

    Norfolk, Virginia

  • Research Site

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.